Transcription
UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINECurriculum VitaeDate: 07/19/2021Lynn Mara Schuchter, M.D.Address:Division of Hematology OncologyPerelman Center for Advanced MedicineIf you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have:none (U.S. citizen)Education:19781982B.S.M.D.University of MichiganChicago Medical SchoolPostgraduate Training and Fellowship Appointments:1982-1983Intern, Department of Medicine, Michael Reese Hospital,Chicago, IL1983-1985Resident, Department of Medicine, Michael Reese Hospital,Chicago, IL1985-1986Chief Medical Resident, Department of Medicine, MichaelReese Hospital, Chicago, IL1986-1989Clinical Fellow, Medical Oncology, The Johns HopkinsOncology Center Baltimore, MD1987Visiting Fellow, Biologic Response Modifier Program, NCI,Frederick, MD2016-2018Hospice & Palliative Medicine Fellowship, Hospital of theUniversity of Pennsylvania, Philadelphia, PAMilitary Service:[none]Faculty 011-presentAssistant Professor of Medicine, University of PennsylvaniaSchool of MedicineAssistant Professor of Medicine at the Hospital of theUniversity of Pennsylvania, University of PennsylvaniaSchool of MedicineAssociate Professor of Medicine at the Hospital of theUniversity of Pennsylvania, University of PennsylvaniaSchool of MedicineProfessor of Medicine at the Hospital of the University ofPennsylvania, University of Pennsylvania School of MedicineC. Willard Robinson Professor of Hematology-Oncology,University of Pennsylvania School of Medicine
Lynn Mara Schuchter, M.D.Page 2Hospital and/or Administrative Appointments:1985-1986Clinical Instructor, Department of Medicine, University ofChicago Hospital and Clinics1985-1986Associate Attending Physician, Department of Medicine,Michael Reese Hospital1989-presentAttending Physician, Hospital of the University ofPennsylvania2007-2008Interim Division Chief-Hematology/Oncology, University ofPennsylvania2008-presentDivision Chief, Hematology-Oncology, University ofPennsylvania2018-presentDirector, Tara Miller Melanoma Center, Abramson CancerCenterOther 009-20112016-present2017-presentSpecialty Certification:198619902018Licensure:1989Director, Clinical Research Unit, Abramson Cancer Center ofthe University of PennsylvaniaCo-Program Leader, Clinical Investigations Program,Abramson Cancer Center of the University of PennsylvaniaProgram Leader, Clinical Investigations Program, AbramsonCancer Center of the University of PennsylvaniaProgram Leader: Melanoma Program, Abramson CancerCenter of the University of PennsylvaniaAssociate Director, Clinical Research Unit, Abramson CancerCenter of the Hospital of the University of PennsylvaniaInternal Advisory Board Member, University of PennsylvaniaCenter for Health Incentives and Behavioral EconomicsInternal Advisory Board Member, Palliative and AdvancedIllness Research Center (PAIR)American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine SubspecialtyCertification in Medical OncologyAmerican Board of Internal Medicine (Hospice & PalliativeMedicine)License to Practice Medicine, State of PennsylvaniaAwards, Honors and Membership in Honorary Societies:1981Alpha Omega Alpha1985A.A. Goldsmith Humanitarian Award, Michael Reese Hospital1986-1987Clinical Fellowship Award, American Cancer Society1988-1989Trainee, National Research Service Award
Lynn Mara Schuchter, 017201720192020Page 3American Cancer Society: Career Development AwardJohn Glick Teaching AwardBest Doctors in AmericaRiza Lavizzo-Mourey Visiting ProfessorshipDepartment of MedicineSusan Fazio Award for Melanoma ResearchHumanitarian Award, Melanoma Research Foundation Wings of Hope for Melanoma PhiladelphiaLouis Duhring Outstanding Clinical Specialist Award - PennMedicineFOCUS Award for the Advancement of Women inMedicine/Perelman School of Medicine at the University ofPennsylvaniaWomen on the Move/Main Line Today, Newtown Square, PAAbramson Cancer Center Philly Fights Cancer: Round 3 HonoreeHologic, Inc Endowed Women Who Conquer CancerMentorship Award/ Conquer Cancer The ASCO FoundationWomen Who Conquer CancerProvider Patient Experience Champion of the Year/ClinicalPractices of the Hospital of the University of Pennsylvania(CPUP)Memberships in Professional and Scientific Societies and Other Professional Activities:College of Physicians, Philadelphia (Member)Society of Biological Therapy (Member, 1991-1995)Society of Melanoma Research (Member-2004)National:1989-PresentAmerican Society of Clinical Oncology (ASCO) (Member, 1989Board of Directors: 2009 - 2012Board of Directors: Education Subcommittee 2009-2012Board of Directors: Planning Subcommittee 2009-2012Cancer.Net Advisory Panel: 2008Timely Oncology Perspectives (TOPs)Team 2009-2013)ASCO-SSO Sentinel Node Biopsy (SNB) in Melanoma Member 2008-2018Cancer Research Committee: 2004-presentCancer Research Audit Committee: 2009-2010Cancer Research Strategic Planning: 2009-2012Cancer Research Committee, Chair: 2013-2014
Lynn Mara Schuchter, M.D.Page 4Co-Chair- Chemo/Radio Protectants Expert Panel: 1998-2012ASCO Maintenance of Certification Task Force: 2005-2007Scientific Program Committee Subcommittee ientific Program Committee Chair:2015Education Committee: 1995,1996,1997,2003-2004Public Issues Committee:2002-2004Chair:2003-2004Cancer Communication Committee: 1993-1998Vice Chairman: 1994-1996Chairman: 1996-1998Board Liaison: 2009-2012Executive Editor: 2013-2014News Planning Team, Chair: 2016 inaugural ASCO-SITC Clinical ImmunoOncology Symposium)1992-2005American College of Physicians (Member, 1992PIER Review: Melanoma Module)1993-PresentMembership in National Scientific Review Panels:National Institutes of Health (ad hoc Member, NIH, CTEP, Grant Reviewer 1992,1993ad hoc Member, NIH, GCRC, Grant Reviewer 1993, 1994, 1995, 1996ad hoc Member, NIH, RFA, Grant Reviewer 1994ad hoc Member, NIH, POI, Grant Reviewer 1995ad Hoc Member, FDA Orphan Drug Program1995ad Hoc Member, NIH POI, Grant Reviewer1995NIH Clinical Oncology Study Section - Member1999-2000NCI IRG-Subcommittee A for Cancer Center Reviews Study Sectioneffective 7/1/05-presentad Hoc Reviewer, NCI SPORE Grant Review-2007)
Lynn Mara Schuchter, M.D.1995-2002Page 5American Board of Internal Medicine (Secretary, Subspecialty Committee in MedicalOncology)SEP Medical Oncology: Committee 2006)2006-PresentMelanoma Research Foundation: Member (Scientific Advisory Committee: Memberand Past Chair,Board of Directors: Former Board Member)Editorial -20032005-20082005-20072009-2012Medical Editor, University of Pennsylvania Cancer CenterNewsletterPDQ Editorial Board, NCIEditorial Member, Journal of Clinical OncologyEditor: Melanoma Section, Current Opinion in OncologyEditor: Skin Cancer, Current Treatment Options in OncologyEditor, Journal of Clinical OncologyEditorial Board: Journal of Clinical OncologyAssociate Editor, Cancer.Net American Society of ClinicalOncology (ASCO)Academic and Institutional Committees:1990-2005General-Clinical Research Center (GCRC) Advisory CommitteeMemberVice Chair: 2003-20051993-PresentClinical Trials Scientific Review and Monitoring Committee:Cancer CenterVice-Chairman 1993-1995Chairman 1995-1997Chair-Auditing subcommittee 1997-20011995-1997Drug and Usage Subcommittee Member1995-1999Institute for Human Gene Therapy (Member)1995-1996Patient Oriented Research Task Force1997-1999Intern Selection Committee1999-2009University Research Foundation Committee2002-2008Faculty Advisory Committee-Office of Human Research2002-2006University of Pennsylvania IRBVice Chair: 2004-2005Chair: IRB-2005-20062004-2005Committee to Review Epidemiology and Biostatistics GraduateGroup2006-2009Advisory Committee on Women: Dept of Medicine2006-2010Clinical Research Advisory Committee-Member: ExecutiveCommittee2007-2008Department of Medicine COAP-member
Lynn Mara Schuchter, nt2017-Present2018-Present2019-PresentPage 6Member, Perelman Center for Advanced Medicine - PhysiciansGovernance CommitteeExecutive Steering Committee, Abramson Cancer Center at theUniversity of PennsylvaniaExecutive Committee, Perelman Center for Advanced Medicine Cancer Service LineCo-leader, Hematology/Oncology Quality Cancer Care CommitteeMember, Business Development Committee - Regional CancerProgramExecutive Committee, Penn Medicine and Penn Princeton CancerProgramMember, Diversity Equity Inclusion Committee, Penn HematologyOncologyMajor Academic and Clinical Teaching Responsibilities:1990-PresentSupervision of Medical Oncology Fellows in Weekly Clinic1997-PresentAdult Oncology Nurse Practitioner CourseN666 Nursing Management and the Effects of Cancer and CancerTherapyUniversity of Pennsylvania School of NursingBiotherapy, Vaccine Therapy, and Gene Therapy2002Clinical Applications of Oncology DrugsFirst Year Medical Students2003-2004Doctoring I2003-2004GCP: Introduction to Patient Oriented ResearchSchool of Medicine2004-2009EP: Phase II Clinical Trial Design2007-2008LEAP: First Year Medical Students:2007-2009EP: Conducting Clinical Research: Good Clinical PracticeCourse to Fellows in Conduct of Clinical Research2007-PresentSupervision of First Year Medicine Intern in Outpatient OncologyPractice2018Roy and Diana Vagelos Program in Life Science and Management(LSM) "Decision Resources Lecture in Life Sciences andManagement" Distinguished LecturerLectures by Invitation (Last 5 years):Jan, 2016"New immunotherapy approaches for the treatment of melanoma Can advanced melanoma be cured?" The Children's Hospital ofPhiladelphia, Philadelphia, PAMay, 2016"Curing advanced melanoma: Becoming a real possibility" WillsEye Hospital Intraocular Tumor Symposium, Philadelphia, PAMay, 2016"Putting it All Together: What every patient should know aboutMelanoma" Penn Medicine, Abramson Cancer Center, Focus onMelanoma, Philadelphia, PASep, 2016Metastatic Melanoma Potentially Curable? Cancer Symposium,
Lynn Mara Schuchter, M.D.Sep, 2016May, 2017Nov, 2017Oct, 2018Nov, 2018Dec, 2018Oct, 2019Jun, 2020Oct, 2020Dec, 2020May, 2021Page 7Doylestown Health, Doylestown Hospital, Doylestown, PA"Managing Common Dose-Limiting Toxicities" ASCO PalliativeCare in Oncology Symposium, San Francisco, CA"Focus on Melanoma""Recent Advances in Oncology for the Primary Care Physician Virtua", Penn Medicine, Abramson Cancer Center of the Universityof Pennsylvania"Confronting Melanoma in all its Forms and Stages" Keynote Melanoma Action Coalition Fall Conference, Philadelphia, PA"Cutaneous Oncology"/Sixteenth Wallace H. Clark Jr., MDLectureship in Cutaneous Oncology/University of Pennsylvania"Penn Medicine Inaugural Student Clinician's Ceremony"Reflection on a 30 Year Career" The Conquer Cancer Foundationof ASCO, 2019 Conquer Cancer Scientific and Career DevelopmentRetreat, Washington, DC"Impact of COVID-19 on the Delivery of Cancer Care / Cancer andCOVID-19: Update from Penn's Abramson Cancer Center""A Decade of Advancement: Harnessing the Patient ImmuneSystem" LEAD Conference for Women in Oncology, Bio Ascend, aVaniam Group Company, Virtual"Understanding New Approached to Cancer Treatment - TargetedTherapy and Immunotherapy / Recent Advance in Oncology 2020Virtual Meeting"18th Focus on Melanoma" Penn Medicine, Abramson CancerCenter, VirtualOrganizing Roles in Scientific Meetings:Nov, 2007Society of Melanoma Research Melanoma CongressChairman and Moderator of Clinical/Translational MelanomaSessionNew York, NYApr, 2008Translational Research: Focus MelanomaAACR Annual MeetingSession Co-ChairSan Diego, CASep, 2008Oncology Congress: Melanoma SessionSan Francisco, CAMar, 2013Planning Committee member and speaker, Recent Advances inOncology for the Primary Care Physician. Abramson Cancer Centerof the University of Pennsylvania.Valley Forge, PAJun, 2013Planning Committee Member and Speaker, 2013 Updates inOncology: With Proceedings from International Medical Meetings.Perelman School of Medicine of the University of PennsylvaniaPhiladelphia, PANov, 2018Activity Co-Director 16th Wallace H. Clark Jr., MD Lectureship in
Lynn Mara Schuchter, M.D.Jun, 2019Nov, 2019Sep, 2020Sep, 2020Oct, 2020Nov, 20202020May, 2021Page 8Cutaneous Oncology & Melanoma SymposiumClark Lectureship: Adjuvant Therapy for Melanoma: Headspinning ProgressPenn Medicine's Abramson Cancer Center, Arthur RubensteinAuditorium, Philadelphia, PACo-Director, Updates in Oncology 2019 Philadelphia withProceeding from International Medical MeetingsThe Rittenhouse Hotel, Philadelphia PACo-Chair/A Seat at the Table-Removing Barriers and Bias forWomen in OncologyPenn Medicine/Abramson Cancer Center, Philadelphia, PACo-Conference Chair, CANCER and COVID-19: Update fromPenn's Abramson Cancer CenterUniversity of Pennsylvania/Abramson Cancer Center / Philadelphia,PA VirtualChair/Cancer and COVID-19: Update from Penn's AbramsonCancer CenterUniversity of Pennsylvania/Abramson Cancer Center/ Philadelphia,PA VirtualCo-Chair, Conquer Cancer The ASCO Foundation, Women WhoConquer Cancer, LEAD Conference for Women in OncologyVirtualHost/Women Who Conquer CancerPhiladelphia, PA VirtualActivity Co-Director/Recent Advances in Oncology 2020 VirtualMeetingUniversity of Pennsylvania, Abramson Cancer Center, Philadelphia,PAConference Chair, 18th Focus on MelanomaVirtualBibliography:Research Publications, peer reviewed (print or other media):1. Schuchter, L.M., Wingard, J.R., Piantadosi, S., Burns, W.H., Santos, G.W., Saral, R.:Herpes Zoster Infection Following Autologous Bone Marrow Transplantation.Blood 74(4): 1424-1427, 1989.2. Fishman, E.K, Kuhlman, J.E., Schuchter, L.M., Miller, J.A., Magid, D.: CT ofMalignant Melanoma in the Chest, Abdomen and Musculoskeletal System.Radiographics 10(4): 603-620, 1990.3. Schuchter, L.M, Hendricks, C.B., Holland, K.H., Shelton, B.K., Hutchins, G.M.,Baugham, K.G., Ettinger, D.S.: Eosinophilic Myocarditis Following Interleukin-2Treatment. Am J of Med 88(4): 439-440, 1990.4. Kawashima, A., Fishman, E.K., Kuhlman, J.E., Schuchter, L.M.: CT of Malignant
Lynn Mara Schuchter, M.D.Page 9Melanoma: Patterns of Small Bowel and Mesenteric Involvement. Journal ofComputer Assistant Tomography 15(4): 570-574, 1991.5. Schuchter, L.M., Esa, A.H., May, W.S., Pettit, G.R., Laulis, M.K., Hess, A.D.:Successful Treatment of Murine Melanoma with Bryostatin-1. Cancer Res 51:682-687, 1991.6. Meropol, N.J., Miller, L., Korn, E.L., Braitman, L.E., MacDermott, M.L., Schuchter,L.M.: Severe Myelosuppression Resulting from Concurrent Administration ofGranulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy. J NatlCancer Inst 84(15): 1201-1203, 1992.7. Redmond, H.P., Schuchter, L.M., Bartlett, D., Kelly, C.J., Shou, J., Leon, P., Daly,J.M.: Anti-Neoplastic Effects of Interleukin-4. J Surg Res 52(4): 406-411, 1992.8. Schuchter, L.M., Wohlganger, J., MacDermott, M., Fishman, E., McGuire, W.P.:Sequential Chemotherapy and Immunotherapy for the Treatment of MetastaticMelanoma. J Immunother 12(4): 272-276, 1992.9. Halpern, A.C., Schuchter, L.M., Elder, D.E., Guerry, D., Elenitsas, R., Trock, B.,Matozzo, I.: Effects of Topical Tretinoin on Dysplastic Nevi. J Clin Oncol 12(5):1028-1035, 1994.10. Nakashima, M., Janiszewska, M., Steplewski, Z., Watanabe, T., Schuchter, L.,Koprowski, H.: Proliferation, Phenotype, and Cytotoxicity of HumanLymphocytes Isolated from Lymph Nodes Invaded by Melanoma Cells.Hybridoma 13(3): 241-246, 1994.11. Nakashima, M., Watanabe, T., Koprowski, H., Schuchter, L., Steplewski, Z.: In VitroExpansion of Tumor Specific, HLA-Restricted CD8 Cytolytic T-lymphocytes.Cellular Immunology 155(1): 53-61, 1994.12. Einzig, A.I., Schuchter, L.M., Rodriguez, R., Coatsworth, S., Wiernik, P.H., Recio,A.: Phase II Trial of Docetaxel (Taxotere) in Patients with Metastatic MelanomaPreviously Untreated with Cytotoxic Chemotherapy. Medical Oncology 13(2):111-117, 1996.13. Greco, F.A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marchsll, E.M., Buys,S.S., Froimtchuk, M.J., Schuller, J., Schuchter, L., Buyse, M., Ritter, L., Man, A.,Yap, A.K.: Phase III Tandomized Study to Compare Interferon Alfa-2A inCombination with Fluorouracil versus Fluorouracil Alone in Patients withAdvanced Colorectal Cancer. J Clin Oncol 14(10): 2674-2681, 1996.14. Martenseon, J.A., Lipsitz, S.R., Wagner, H., Kaplan, E.H., Otteman, L.A., Schuchter,L.M., Mansour, E.G., Talamonti, M.S., Benson, A.B.: Initial Results of a Phase IITrial of High Dose Radiation Therapy, 5 Fluorouracil and Cisplatin for Patients
Lynn Mara Schuchter, M.D.Page 10with Anal Cancer (E4292): An Eastern Cooperative Oncology Group Study. IntJ Radia Oncol Biol Phys 35(4): 745-749, 1996.15. Schuchter, L.M., Schultz, D.J., Synnestevdt, M., Trock, B.J., Guerry, D., Elder, D.,Elenitsas, R., Clark, W.H., Halpern, A.C.: A Prognostic Model Predicting 10 YearSurvival in Patients with Primary Melanoma. The Pigmented Lesion Group. AnnIntern Med 125(5): 369-375, 1996.16. Anbari, K., Schuchter, L.M., Bucky, L., Mick, R., Synnestvedt, M., Guerry, D.,Hamilton, R., Halpern, A.: Melanoma of Unknown Primary Site: Presentation,Treatment and Prognosis in a Single Institution Study, University of PennsylvaniaPigmented Lesion Study Group. Cancer 79(9): 1816-1821, 1997.17. Berd, D., Maguire, H.C., Schuchter, L.M., Hamilton, R., Hauck, W.W., Mastrangelo,M., Sato, T.: Autologous Hapten-Modified Melanoma Vaccine as Post-SurgicalAdjuvant Treatment After Resection of Nodal Metastases. J Clin Oncol 15(6):2359-2370, 1997.18. Alpaugh, R.K., von Mehren, M., Palazzo, I., Atkins, M., Sparano, J.A., Schuchter, L.,Weiner, L., Dutcher, J.P.: Phase IB Trial for Malignant Melanoma Using R24Monoclonal Antibody, Interleukin-2/alpha Interferon. Medical Oncology 15(3):191-198, 1998.19. DiPaola, R., Goudins, S., Rodriquez, R., Orlick, M., Mollman, J., Bird, S., Belsh, J.,Schuchter, L.M.: Amifostine and Dose Intensive Paclitaxel in Patients withAdvanced Malignancies. Cancer Therapeutics 1: 11-17, 1998.20. Margolis, D.J., Halpern, A.C., Rebbeck, T., Schuchter, L., Barnhill, R.L., Fine, J.,Berwick, M.: Validation of a Melanoma Prognostic Model. Arch Dermatol134(2): 1597-1601, 1998.21. Chapman, P.B., Einhorn, L.H., Meyers, M.L., Saxman, S., Destro, A.N., Panageas,K.S., Begg, C.B., Arawala, S.S., Schuchter, L.M., Ernstoff, M.S., Houghton,A.N., Kirkwood, J.M.: Phase III Multicenter Randomized Trial of the DartmouthRegimen Versus Dacarbazine in Patients with Metastatic Melanoma. J Clin Oncol17(a): 2745-2751, 1999.22. Hensley, M.L., Schuchter, L.M., Lindley, C., Meropol, N.J., Cohen, G.I., Groder, G.,Gradishar, W.J., Green, D.M., Langdon, R.J., Mitchell, R.B., Negrin, R.,Szatrowski, T.P., Thigpen, J.T., Von Hoff, D., Wasseman, T.H., Winer, E.P.,Pfister, D.G.: American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 17(10):3333-3355, 1999.23. Moore, H.C.F., Mick, R., Solin, L., Sickles, C., Mangan, P., Luger, S., Fox, K.R.,Schuchter, L.M., Loh, E., Porter, D., Schuster, S., Buzby, G., Glatstein, E.,
Lynn Mara Schuchter, M.D.Page 11Silberstein, L., Stadtmauer, E.: Autologous Stem-Cell Transplant AfterConventional Dose Adjuvant Chemotherapy for High-Risk Breast Cancer:Impact on the Delivery of Local-Regional Radiation Therapy. Ann Oncol 10(8):929-936, 1999.24. Orel, S.G., Weinstein, S.P., Schnall, M.D., Reynolds, C.A., Schuchter, L., Fraker, D.,Solin, L.: Breast MR Imaging in Patients with Axillary Node Metastases andUnknown Primary Malignancy. Radiology 212(2): 543-549, 1999.25. Stadtmauer, E.A., Tsai, D.E., Sickles, C.M., Mick, R., Luger, S.M., Porter, D.L.,Mangan, P., Schuchter, L.M., Schuster, S., Loh, E., Magee, D., Sachs, R., Wall,M., Moore, J., Buzby, G., Zaleta, E., Kamoun, M., Silberstein, L.: Stem CellTransplantation for Metastatic Breast Cancer: Analysis of TumorContamination. Medical Oncology 16(4): 279-288, 1999.26. Van Belle, P.A., Elenitsas, R., Satyamoorthy, K., Wolfe, J.T., Guerry, D. 4th,Schuchter, L., Van Belle, T.J., Albelda, S., Tahin, P., Herlyn, M., Elder, D.E.:Progression-Related Expression of Beta3 Integrin in Melanomas and Nevi. HumPathol 30(5): 562-567, 1999.27. Bedrosian, I., Sheff, A.M., Callans, L.S., Spitz, R.F., Mick, R., Guerry, D., IV,Schuchter, L., Elenitsas, R., Elder D.E., Bucky, L.P., Fraker, D.L., Czerniecki,B.J.: Incidence of Sentinel Node Metastases in Patients with Thin PrimaryMelanoma ( or 1 mm) with Vertical Growth Phase. Ann Surg Oncol 4: 262267, 2000.28. Visonneau, S., Caesano, A., Porter, D.L., Luger, S.L., Schuchter, L., Kamoun, M.,Torosian, M.H., Duffy, K., Sickles, C., Stadtmauer, E., Santoli, D.: Phase I Trialof TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer. ClinCancer Res 6: 1744-1754, 2000.29. Chang, J.H., Vines, E., Bertsch, H., Fraker, D.L., Czerniecki, B.J., Rosato, E.F.,Lawton, T., Conant, E.F., Orel, S.G., Schuchter, L., Fox, K.R., Zieber, N., Glick,J., H., Solin, L.J.: The Impact of a Multidisciplinary Breast Cancer Center onRecommendations for Patient Management: The University of PennsylvaniaExperience. Cancer 91: 1231-1237, 2001.30. Wildemore, J.K. 4th, Schuchter, L., Mick, R., Synnestvedt, M., Elenitsas, R.,Bedrosian, I., Czerniecki, B.J., Guerry D. 4th, Lessin, S.R., Elder, D.E., Bucky,L.P.: Locally Recurrent Malignant Melanoma Characteristics and Outcomes: ASingle-Institution Study. Ann Plast Surg 46(5): 488-494, 2001.31. Miller, K.D., Gradishar, W., Schuchter, L., Sparano, J.A., Cobleigh, M., Robert, N.,Rasmussen, H., Sledge, G.W.: A Randomized Phase II Pilot Trial of AdjuvantMarimastat in Patients with Early-Stage Breast Cancer. Ann Oncol 13(8): 12201224, August 2002.
Lynn Mara Schuchter, M.D.Page 1232. Anderson, T.D., Weber, R.S., Guerry, D., Elder, D., Schuchter, L., Loevner, L.,Rosenthal, D.I.: Desmoplastic Neurotropic Melanoma of the Head and Neck:The Role of Radiation Therapy. Head Neck 24(12): 1068-1071, December 2002.33. Blackwood, M.A., Holmes, R., Synnestvedt, M., Young, M., George, C., Yang, H.,Elder, D.E., Schuchter, L.M., Guerry, D., Ganguly, A.: Multiple PrimaryMelanoma Revisited. Cancer 94(8): 2248-2255, 2002.34. McGinnis, K.S., Lessin, S.R., Elder, D.E., Guerry IV, D., Schuchter, L.M., Elenitsas,R: Pathology Review of Cases Presenting to a Multidisciplinary PigmentedLesion Clinic. Arch Dermatol 138(5): 617-621, 2002.35. Rebbeck, T.R., Kanetsky, P.A., Walker, A.H., Holmes, R., Halpern, A.C., Schuchter,L.M., Elder, D.E., Guerry, D.: P Gene as an Inherited Biomarker of Human EyeColor. Cancer Epidemiol Biomarkers Prev 11(8): 782-794, 2002.36. Schuchter, L.M., Hensley M.L., Meropol, N.J., Winder, E.P.: 2002 Update of theRecommendations for the use of Chemotherapy and Radiotherapy Protectants:Clinical Practice Guidelines of the American Society of Clinical Oncology. J ClinOncol 20(12): 2895-2903, 2002.37. Stevenson, J.P., Sun, W., Gallagher, M., Johnson, R., Vaughn, D., Schuchter, L.,Algazy, K., Hahn, S., Enas, N., Ellis, D., Thornton, D., O'Dwyer, P.J.: Phase ITrial of the Cryptophycin Analogue LY355703 Administered as an IntravenousInfusion on a Day 1 and 8 Schedule every 21 days. Clin Cancer Res 8(8): 25242529, 2002.38. Loren, A.W., Desai, S., Gorman, R.C., Schuchter, L.M.: Retransplantation of aCardiac Allograft Inadvertently Harvested from a Donor with MetastaticMelanoma. Transplantation 76(4): 741-743, August 2003.39. Lichtenthal, W.G., Cruess, D.G., Schuchter, L.M., Ming, M.E.: Psychosocial FactorsRelated to the Correspondence of Recipient and Provider Perceptions of SocialSupport Among Patients Diagnosed with or at Risk for Malignant Melanoma.Journal of Health Psychology 8(6): 705-719, 2003.40. Schuchter LM.: Adjuvant interferon therapy for melanoma: high-dose, no dose,which dose? J Clin Oncol. 22(1): 7-10, Jan 2004.41. Kanetsky PA, Ge F, Najarian D, Swoyer J, Panossian S, Schuchter L, Holmes R,GUerry D, Rebbeck TR.: Assessment of polymorphic variants in themelnaocortin-1 receptor gene with cutaneous pigmentation using an evolutionaryapproach. Cancer Epidemiol Biomarkers Prev. 13(5): 808-19, May 2004.42. Gimotty, P.A., Guerry, D., Ming, M., Elenitsas, R., Xu, G., Czerniecki, B., Spitz, F.,
Lynn Mara Schuchter, M.D.Page 13Schuchter, L., Elder, D.: Thin Primary Cutaneous Malignant Melanoma: APrognostic Tree for Ten-Year Metastasis is More Accurate than AJCC Staging.Journal of Clinical Oncology 22(18): 3668-76, Sept 2004.43. Fuster, D., Chiang, S., Johnson, G., Schuchter, L.M., Zhuang, H., Alavi, A.: Is 18FFDG PET More Accurate Than Standard Diagnostic Procedures in the Detectionof Suspected Recurrent Melanoma? Journal of Nuclear Medicine 45(8): 13231327, 2004.44. Kanetsky, P., Ge F., Najarian, D., Swoyer, J., Panossian, S., Schuchter, L., Holmes,R., Guerry, D., Rebbeck, T.R.: Assessment of Polymorphic Variants in theMelanocortin-1 Receptor Gene with Cutaneous Pigmentation Using anEvolutionary Approach. Cancer Epidemiol Biomarkers Prev 13(5): 808-819,2004.45. Smith, K, Wray L, Klein-Cabral, M, Schuchter L, Fox K, Glick J, DeMichele A.:Ethnic Disparities in Adjuvant Chemotherapy for Breast Cancer are not Causedby Excess Toxicity in Black Patients. Clinical Breast 6(3): 260-266, August 2005.46. Zhang, T, Somasundaram, T, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S,Schuchter L, Fraker D, Spitz F, Berencsi P, Marincola F, Qui R, Herlyn D.:Preferential Involvement of CX-Chemokine Receptor and CX-Chemokine Ligand-12 in T-cell Migration Toward Melanoma Cells. Journal of Leucocyte BiologyOct 2005.47. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, DemetriGD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH,Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ,Mayer RJ. American Society of Clinical Oncology.: Clinical Cancer Advances2005: major research advances in cancer treatment, prevention, and screening--areport from the American Society of Clinical Oncology. J Clin Oncol 24((1)):190-205, Jan 2006.48. Jackson BM, Kim S, Davidson, R, Schuchter L, Acs G, Czerniecki BJ.: Repeatoperative sentinel lymph node biopsy. Clin Breast Cancer. PMID, 6((6)): 530-2,Feb 2006.49. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P,Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, HerlynD.: Human leukocyte antigen-A2-restricted CTL responses to mutated BRAFpeptides in melanoma patients. Cancer Res 66((6)): 3287-93, Mar 2006.50. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, Van Belle P,Hotz S, Elder DE, Marcinola FM, Schuchter L, Guerry D, Czerniecki BJ, HerlynD.: Human leukocyte antigen-A2-restricted CTL responses to mutated BRAFpeptides in melanoma patients. Cancer Res 66((6)): 3287-93, March 2006.
Lynn Mara Schuchter, M.D.Page 1451. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S,James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, PoulinCostello M, O'Dwyer PJ, Ratain MJ.: Sorafenib in advanced melanoma: a PhaseII randomized discontinuation trial analysis. Br J Cancer 95((5)): 581-6, Sept2006.52. Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, CzernieckiB, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R,Herlyn D.: Preferential involvement of CX chemokine receptor 4 and CXchemokine ligand 12 in T-cell migration toward melanoma cells. Cancer BiolTher. Epub 2006 Oct 4, 5((10)): 1304-12, Oct 2006.53. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME,Schuchter L, Spitz FR, Czerniecki BJ, Guerry D.: Identification of high-riskpatients among those diagnosed with thin cutaneous melanomas. J Clin Oncol.(eds.). 25(9): 1129-34, Mar 2007.54. Swoboda RK, Somasundaram R, Caputo L Ochoa EM, Gimotty PA, Marcinola FM,Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter, L,Vonderheide RH, Herlyn D.: Shared MHC class II-dependent melanomaribosomal protein L8 identified by phage display. Cancer Res 67(8): 3555-9, Apr2007.55. Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A,Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E,Feldman MD, Vonderheide RH: Telomerase-specific T-cell immunity in breastcancer: effect of vaccination on tumor immunosurveillance. Cancer Research67(21): 10546-55, Nov 1 2007.56. Gralow Julie, Ozols Robert F, Bajorin Dean F, Cheson Bruce D, Sandler Howard M,Winer Eric P, Bonner James, Demetri George D, Curran Walter, Ganz Patricia A,Kramer Barnett S, Kris Mark G, Markman Maurie, Mayer Robert J, RaghavanDerek, Ramsey Scott, Reaman Gregory H, Sawaya Raymond, Schuchter Lynn M,Sweetenham John W, Vahdat Linda T, Davidson Nancy E, Schilsky Richard L,Lichter Allen S, : Clinical cancer advances 2007: major research advances incancer treatment, prevention, and screening--a report from the American Societyof Clinical Oncology. Journal of Clinical Oncology 26(2): 313-25, Jan 2008.57. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C,Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, BroseMS, Weber BL, Albertini MR, O'Dwyer PJ: A phase I trial of the oral,multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.Clin Cancer Research 14(15): 4836-42, Aug 2008.58. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,
Lynn Mara Schuchter, M.D.Page 15Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, von HoffD, Schuchter LM: American Society of Clinical Oncology 2008 clinical practiceguideline update: use of chemotherapy and radiation therapy protectants. J ClinOncol 27(1): 127-45, Jan 2009.59. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, KaplanDE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, SchuchterLM, Vonderhei
Perelman Center for Advanced Medicine . 2011-present C. Willard Robinson Professor of Hematology-Oncology, . 1999-2003 Editor: Skin Cancer, Current Treatment Options in Oncology 2005-2008 Editor, Journal of Clinical Oncology 2005-2007 Editorial Board: Journal of Clinical Oncology .
